| abstract |
(57) [Summary] The present invention provides a therapeutically acceptable heparin-binding protein capable of inhibiting the binding of a heparin-binding protein to a low-affinity heparin-like binding site on the cell surface of an organ that is sufficiently perfused with blood. It also relates to a method for prolonging the plasma half-life of a heparin-binding protein, which method comprises co-administration with a possible compound. The inhibitor compound can be, for example, a purified natural heparin preparation, a heparin fragment, or other polyanionic compound such as dextran sulfate, heparin sulfate, pentosan sulfate, hyaluronate. |